Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022

Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022




Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022

AUSTIN, Texas, & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Senior Management will participate in four upcoming healthcare investor conferences.

  • Oppenheimer Private Company Showcase: The Next Wave: presentation at 2:35 pm PT on Tuesday, October 18th and available for investor meetings
  • Bank of America Healthcare Life Sciences Private Company Conference: available for in-person investor meetings on Thursday, October 20th
  • Wells Fargo Private Biotech Symposium: available for virtual investor meetings on Wednesday, November 2nd
  • Stifel 2022 Healthcare Conference: presentation on Wednesday, November 16th at 9:10 am ET and available for investor meetings

About Triumvira Immunologics

Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira’s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon® Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.

Contacts

Investor Relations:
Stephanie Carrington

ICR Westwicke

Stephanie.Carrington@westwicke.com
646-277-1282

Media Relations:
Karen Chase

ICR Westwicke

Karen.Chase@westwicke.com